Peer reviewed
The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis.
BMC Gastroenterology (2020). The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis.
BMC GastroenterologyAccessed Aug 5, 2026
Registry record
Source metadata
- Publisher
- BMC Gastroenterology
- Source type
- Peer reviewed
- Registry ID
pubmed-ta1-entecavir-meta-2020- DOI
- 10.1186/s12876-020-01477-8
- PMID
- 33076834
Source usage
Not yet linked from a public content page
This record may be retained for an upcoming review or for internal source normalization.
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.